Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003223 · ClinicalTrials.gov registry record · Phase 2
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00003223 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 5 participants.
The verdict
NCT00003223, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide may be an effective way to prevent the development of cancer in patients with neoplasia of the mouth. PURPOSE: Phase II trial to study the effectiveness of fenretinide in preventing cancer in patients who have neoplasia of the mouth.
Interventions
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 1997-12 |
| Est. Completion | 2000-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003223
The ClinicalTrials.gov registry entry for NCT00003223 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fenretinide is the first listed.
NCT00003223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003223 about?
NCT00003223 is a clinical study titled "SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of fenretinide may be an effective way to prevent the development of cancer in patients with neoplasia of the mouth. PURPOSE: Phase II trial to study the effectiveness o...
What is the current status of trial NCT00003223?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 1997-12. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00003223?
The interventions under investigation include: fenretinide (DRUG).
Who is sponsoring clinical trial NCT00003223?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.